Current understanding of prostate cancer biomarkers

被引:0
|
作者
Popov, S. V. [1 ,2 ]
Guseynov, R. G. [1 ,2 ,3 ]
Vasin, A. V. [4 ]
Sivak, K. V. [1 ,5 ]
Pomeshkin, E. V. [1 ]
Perepelitsa, V. V. [1 ,2 ]
Bunenkov, N. S. [1 ,6 ,7 ]
Lelyavina, T. A. [7 ]
机构
[1] St Lukas Clin Hosp, 46 Chugunnaya St, St Petersburg 194044, Russia
[2] St Petersburg Med & Social Inst Let, 72 Kondratievskiy Prospekt, St Petersburg 195271, Russia
[3] St Petersburg State Univ, 7-9 Univ Skaya Naerezhnaya, St Petersburg 199034, Russia
[4] Peter Great St Petersburg Polytechn Univ, Inst Biomed Syst & Biotechnol, 29 Polytech Skaya, St Petersburg 195251, Russia
[5] AA Smorodintsev Res Inst Influenza, 15-17 Prof Popova St, St Petersburg 197022, Russia
[6] IP Pavlov First St Petersburg State Med Univ, 6-8 Lva Tolstogo St, St Petersburg 197022, Russia
[7] VA Almazov Natl Med Res Ctr, 2 Akkuratova St, St Petersburg 197341, Russia
来源
ONKOUROLOGIYA | 2023年 / 19卷 / 04期
关键词
prostate cancer; biomarker; prostate biopsy; diagnostics; prognosis; HEALTH INDEX PHI; DIAGNOSTIC PERFORMANCE; GENOMIC CLASSIFIER; BIOPSY; VALIDATION; PREDICTOR; 4KSCORE; MEN;
D O I
10.17650/1726-9776-2023-19-4-148-157
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Worldwide, prostate cancer has remained one of the most common malignant neoplasms among men and it is accompanied by high mortality rates. Standard methods for diagnosing prostate cancer have limited sensitivity and specificity, unnecessary biopsies are often performed, and the risk of overdiagnosis of the disease and overtreatment of patients is high. The review considers diagnostic and prognostic biological markers of prostate cancer proposed in recent years. Theoretical foundations for the use of new biomarkers are analyzed. The characteristics and practical significance of biomarkers of various groups (immunohistochemical, molecular and genetic, prostate specific antigen-associated, volatile organic metabolites) are presented. The need for further large-scale scientific research in the field of biomarker application in prostate cancer, criteria for their selection and evaluation are described. The introduction of modern diagnostic and prognostic markers into real clinical practice opens up new opportunities for improvement of prostate cancer diagnosis, individual prognosis, and rationalization of treatment strategy.
引用
收藏
页码:148 / 157
页数:10
相关论文
共 50 条
  • [1] Current Status of Biomarkers for Prostate Cancer
    Velonas, Vicki M.
    Woo, Henry H.
    dos Remedios, Cristobal G.
    Assinder, Stephen J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (06) : 11034 - 11060
  • [2] Current biomarkers for diagnosing of prostate cancer
    Stephan, Carsten
    Jung, Klaus
    Ralla, Bernhard
    FUTURE ONCOLOGY, 2015, 11 (20) : 2743 - 2755
  • [3] Prostate cancer biomarkers: a current perspective
    Kumar-Sinha, C
    Rhodes, DR
    Yu, JJ
    Chinnaiyan, AM
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2003, 3 (04) : 459 - 470
  • [4] Current analysis of urinary biomarkers for prostate cancer
    Yencilek, Faruk
    Koyuncu, Hakan
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2011, 10 (02): : 11 - 16
  • [5] Current early diagnostic biomarkers of prostate cancer
    Qu, Min
    Ren, Shan-Cheng
    Sun, Yinghao
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (04) : 549 - 554
  • [6] Epigenetic biomarkers in prostate cancer: Current and future uses
    Chiam, Karen
    Ricciardelli, Carmela
    Bianco-Miotto, Tina
    CANCER LETTERS, 2014, 342 (02) : 248 - 256
  • [7] Clinical utility of current biomarkers for prostate cancer detection
    Kim, Jeong Hyun
    Hong, Sung Kyu
    INVESTIGATIVE AND CLINICAL UROLOGY, 2021, 62 (01) : 1 - 13
  • [8] Current state of genetic biomarkers for prostate cancer.
    Cooper, Meghan Anastasia
    Lee, Jae K.
    Pow-Sang, Julio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [9] Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management
    Tonry, Claire
    Finn, Stephen
    Armstrong, John
    Pennington, Stephen R.
    CLINICAL PROTEOMICS, 2020, 17 (01)
  • [10] Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management
    Claire Tonry
    Stephen Finn
    John Armstrong
    Stephen R. Pennington
    Clinical Proteomics, 2020, 17